$IBIO News

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity

iBio, Inc. (IBIO) Presents at 2026 EASD Annual Meeting - Slideshow

HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate

Could iBio (IBIO) Be an Underrated Obesity Stock?

Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5

iBio to Participate in Upcoming Healthcare Investor Conferences

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial

We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Q3 EPS $(0.07) Misses $(0.06) Estimate

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600

iBio Details Generative AI Antigen Platform to Speed GPCR Antibody Discovery and Close “Trust Gap”

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia